23 April 2020

Although the acute phase of the corona crisis needs all our attention, we hope that the current measures as well as new scientific insights will enable us to resume part of normal life after the summer holidays. Although it is uncertain in what format the conference can be organized, we continue with the preparation of the yearly Radboud New Frontiers. So save the date already!
 
In contrast with the incidental rise in communicable diseases such as COVID-2019, the prevalence of chronic, non-communicable diseases is continuously rising, and in the near future we will be unable to handle this increase. Most of these diseases are lifestyle-related. However, individuals at risk and health care professionals find it very difficult to change lifestyle. In addition, to be successful interventions need to be tailored. The best is to detect health derangements early, to intervene as early as possible, thus preventing chronicity. There are many influences on health and health behavior, requiring an optimal interaction between the individual, the healthcare system as well as the physical and social environment. In addition, there are big expectations of the role of technology, like eHealth and mHealth, in relation to prevention.
 
Urgent research questions arise. Should we focus on prevention of diseases, or better aim at increasing functioning and participation, despite disease? Does our current evidenced-based medicine approach, with emphasis on trials, align with the complexity of behavioral change and environmental influences?
 
In this Radboud New Frontiers symposium, organized by the Radboud Institute for Health Sciences (RIHS), we will address the topic of prevention research in relation to health and healthcare from various interesting, and necessary, perspectives. We will put you as clinician or researcher in the ‘action’ mode, challenged by top scientists, by asking you to think about the role prevention can have in your own research or clinical work and to discuss this with other participants.
 
Scientists from Europe and the United States will illustrate prevention across the lifespan, highlighting the importance of tailoring of the content and aim of prevention to the age of the individual. We will also explore the interaction between behavior and environment, and the potential role of technology in changing lifestyle. In workshops you can discuss with others what your work can contribute to health and prevention. We will wrap up with illustrations of methodological approaches that best suit the complexity of prevention and behavioral change.
 
This conference will give researchers and clinicians with different backgrounds and levels of seniority a broad insight into the potential of prevention for the forthcoming decades.
 
Save the date for 12 November 2020: Radboud New Frontiers 2020 - Prevention: the need for a leap forward.
 
Concept program
 
Target audience: Master students, PhD candidates, Postdocs, senior researchers, clinicians
 

Related news items


Frank Walboomers 25-years work anniversary at Radboudumc

17 September 2020

Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.

read more

Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes

17 September 2020

Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.

read more

Annette Schenck appointed professor of Translational Genetics

17 September 2020

Annette Schenck has been appointed professor of Translational Genetics at the department of Neurodevelopmental disorders, with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.

read more

Centuries-old medicine reduces the risk of new cardiovascular disease in heart patients

17 September 2020

Colchicine, an anti-inflammatory drug that has been used for gout for centuries, has been shown to prevent cardiovascular disease in patients who have had a heart attack or are suffering from narrowed coronary arteries. Results of the study are published in the New England Journal of Medicine.

read more

Radboudumc does large-scale research on systemic sclerosis

10 September 2020

In rare diseases, such as systemic sclerosis, it’s often difficult to conduct large-scale research. Rheumatologist Madelon Vonk has managed to follow enough patients with systemic sclerosis for years. The results of her research have been published in BMJ Annal of the Rheumatic Diseases.

read more